CASE REPORT

Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia

Ibrahim Aldoss,[1] Parastou Tizro,[2] Davsheen Bedi,[3] James K. Mangan,[4] Mary C. Clark,[1] David Spencer,[5] Joo Y. Song,[2] Sindhu Cherian,[6] Raju Pillai,[2] Young Kim,[2] Nitin Mahajan,[7] Ketevan Gendzekhadze,[8] Mike James,[7] Kenneth Jacobs,[7] Jan Davidson-Moncada,[7] Stephen J. Forman,[1] Huan-You Wang[3] and Michelle Afkhami[2]

[1]Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA; [2]Department of Pathology, City of Hope, Duarte, CA; [3]Department of Pathology, University of California San Diego, La Jolla, CA; [4]Department of Medicine, Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA; [5]Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; [6]Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA; [7]Wugen, Saint Louis, MO and [8]HLA Laboratory, City of Hope, Duarte, CA, USA

Correspondence: I. ALDOSS - ialdoss@coh.org

https://doi.org/10.3324/haematol.2023.283566



Supplemental Figure 1. Timeline of key events. The patient was originally diagnosed with T-ALL and received the indicated therapies. Following initial response to CD7CAR T cells, the patient was diagnosed with acute myeloid leukemia that originated from the T-ALL as a likely lineage switch relapse. This figure was generated in BioRender.com.